Ipamorelin FAQ: Body Composition, Safety & the Evidence
Does ipamorelin reduce belly fat?
No human trial has tested ipamorelin for belly fat. The most relevant body-weight finding is a 2024 ferret study, where intraperitoneal ipamorelin (1–3 mg/kg) cut chemotherapy-driven body-weight loss by about 24% — weight defence, not fat loss [5]. The growth-hormone pulse it produces favours lean over fat mass mechanistically, but no controlled human body-composition data exist [3].
What are the downsides of ipamorelin?
The biggest downside is the evidence gap: the only published Phase 2 trial (114 adults, 0.03 mg/kg IV twice daily for up to 7 days) missed its primary endpoint — time to first tolerated meal was 25.3 h versus 32.6 h on placebo (p = 0.15) [3]. There is no long-term human safety data, and a related ghrelin-receptor drug showed heart-muscle damage in rats over 28 days [6].
Does ipamorelin make you hungry?
It can. Ipamorelin acts on the ghrelin receptor — the body's hunger switch — so increased appetite is a mechanistically expected, occasionally-reported effect, described in community accounts as milder than with older peptides like GHRP-6 [1]. A 2026 Sports Medicine review noted favourable animal metabolic signals but emphasised that rigorous human safety data are scarce.
Does ipamorelin increase appetite?
Yes, increased appetite is plausible and occasionally reported. As a ghrelin / GHS-R1a receptor agonist, ipamorelin activates the same appetite circuitry the natural hunger hormone uses [1]. Community reports describe a hunger uptick in the hours after injection, milder than older GHRPs. This is a class-level mechanism effect, not a documented clinical finding, and it is not tied to any specific dose.
Does ipamorelin cause water retention?
Mild, transient water retention is occasionally reported by the research-use community, especially in the first two to four weeks, and described as milder than with older GHRP compounds [3]. Mechanistically, growth-hormone excess is linked to sodium and water retention. No controlled human study has measured fluid balance on ipamorelin, so this rests on community report and GH-axis mechanism, not trial data.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively triggers the pituitary to release growth hormone by activating the ghrelin receptor (GHS-R1a) [1]. Its defining trait is selectivity: in its 1998 founding study it released GH potently in rats and pigs without raising cortisol or prolactin even at doses 200-fold above its GH-releasing dose [1]. It is not FDA-approved.
What does ipamorelin do for you?
In studies, ipamorelin produces a clean pulse of growth hormone without a stress-hormone spike [1]. In animals it drove dose-dependent bone growth [4] and defended body weight under chemotherapy stress [5]. The recovery, sleep, and leaner-look benefits people associate with it are anecdotal community reports, not trial findings — and no controlled human trial has demonstrated a body-composition benefit [3].
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — built with non-natural residues that resist enzymatic breakdown, derived from the earlier peptide GHRP-1 [1]. Molecular formula C38H49N9O5, weight ~711.9 Da, CAS 170851-70-4. It is the prototype selective growth hormone secretagogue and mimics ghrelin at the GHS-R1a receptor; it is not an endogenous human peptide.
What are the risks of ipamorelin?
The central risk is the unknown: no Phase 3 trial, no long-term human safety database, and the one Phase 2 efficacy trial failed [3]. Class-level concerns include heart-muscle damage seen with a related ghrelin-receptor drug in rats [6], theoretical IGF-1-related proliferation concerns from GH-axis stimulation, and unverified purity of research-grade material from unregulated suppliers.
Why is ipamorelin being discontinued?
Ipamorelin's clinical development effectively stopped because its only Phase 2 trial — for postoperative ileus — missed its primary endpoint (25.3 h vs 32.6 h to first tolerated meal, p = 0.15) [3]. It was never approved as a drug. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A compounding list, tightening pharmacy access.
What does CJC-1295 and ipamorelin do?
CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-receptor agonist) are paired because they trigger growth-hormone release through two complementary pathways at once [1]. The combination is promoted for body composition and recovery, but it has never been tested as a unit in a controlled trial — its rationale rests entirely on the separate pharmacology of each peptide.
Does ipamorelin increase IGF-1?
Not reliably in short studies. In the 15-day rat bone-growth study, ipamorelin raised bone growth in a dose-dependent way without changing total IGF-1 or its binding proteins [4]. Growth hormone can raise hepatic IGF-1 over sustained protocols, but ipamorelin's effect was not consistently IGF-1-mediated in the short rodent work on record.
How does CJC-1295 ipamorelin work?
Each peptide hits a different growth-hormone trigger. Ipamorelin activates the ghrelin receptor (GHS-R1a) through a calcium pathway [1]; CJC-1295, a GHRH analog, works through the GHRH receptor's cAMP pathway. Used together they engage both GH-release routes, which is the mechanistic rationale for the pairing — though no controlled trial has tested the combination for any outcome.
How much CJC-1295 ipamorelin should I take?
This site does not provide dosing. No controlled human trial has established a dose for the CJC-1295/ipamorelin combination, or for ipamorelin alone for body composition [3]. The only human ipamorelin doses on record are research doses — IV infusions in a pharmacokinetic study [2] and 0.03 mg/kg IV twice daily in the failed ileus trial [3]. Community subcutaneous regimens have no peer-reviewed human basis.
Does CJC-1295 ipamorelin work?
The mechanism is coherent and the single-agent animal data is encouraging, but no controlled human trial has shown the combination works for any outcome [3]. Ipamorelin's human record is one pharmacokinetic study [2] and one failed efficacy trial [3]. 'Works' as a proven human result is not established — the pairing rests on each peptide's separate pharmacology, not on combination-trial evidence.
How to reconstitute CJC-1295 ipamorelin 5mg?
There is no validated human reconstitution protocol this site can point to. In general research-supply terms, lyophilized peptides are reconstituted with bacteriostatic water and kept refrigerated, degrading with heat and freeze-thaw. The specific milligram preparations shared online carry no peer-reviewed human basis [3], and this site describes only what published studies administered — it does not give preparation instructions for personal use.
How long does ipamorelin stay in your system?
Ipamorelin's terminal half-life is approximately 2 hours in healthy human volunteers given it intravenously, with clearance 0.078 L/h/kg [2]. The growth-hormone pulse it triggers peaks at about 40 minutes (0.67 h) after dosing and is brief and self-limiting rather than sustained [2]. Subcutaneous pharmacokinetics in humans were never characterised.
Will I gain weight on ipamorelin?
The direction is not predictable from the evidence. Ipamorelin can increase appetite via the ghrelin receptor (a 'gain' lever) while its GH pulse favours lean over fat mass (a 'lean' lever) [1]. In animals it defended body weight under stress rather than driving fat gain [5]. No controlled human body-composition trial exists [3], so no honest source can promise a direction — it depends on the individual, diet, and training.
What does ipamorelin peptide do?
Ipamorelin peptide selectively makes the pituitary release a clean pulse of growth hormone via the ghrelin receptor, without raising cortisol or prolactin [1]. In animals that pulse drove bone growth [4] and defended body weight under stress [5]. The sleep, recovery, and body-composition benefits people associate with it are anecdotal reports, not trial findings, and it has no approved human use [3].
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes after an intravenous dose [2]. For the subjective effects people report — sleep, recovery — community accounts describe first impressions within one to two weeks, but these are anecdotal, unverified, and not measured in any trial [3]. There is no validated timeline for a body-composition result, because no human body-composition trial exists.
Where to inject CJC-1295 ipamorelin?
This site does not give administration instructions. In the research literature, ipamorelin was given intravenously in human studies [2][3] and subcutaneously in rodent work [4]; subcutaneous self-administration is the common off-label community route but has no published human safety or pharmacokinetic characterisation. We describe routes that were studied, not how a person should inject.
Does ipamorelin cause cancer?
No ipamorelin study has shown it causes cancer, and none has tested cancer risk in humans [3]. The theoretical concern is mechanistic: growth hormone raises IGF-1, a growth signal that promotes cell proliferation, so chronically raising GH pulses raises a general, unresolved question about tumour promotion [1]. This is a class-level theoretical caution, not a finding — no oncologic events were reported in the trials run.